Resectable Pancreatic Carcinoma Clinical Trial
Official title:
Open Label Randomized Trial of Blood Transfusions in Cancer Patients Following a Pancreatectomy: A Feasibility Study
This clinical trial tests the the feasibility of testing a red blood cell transfusion threshold for improved quality of life for patients undergoing a pancreatectomy for pancreatic cancer. Pancreatectomy can be associated with significant blood loss. Blood loss can result in clinically important anemia causing fatigue. Pancreatic cancer itself can be associated with malnutrition and fatigue. Having a red blood cell transfusion threshold that results in a more liberal use of transfusions may improve quality of life for patients undergoing a pancreatectomy for pancreatic cancer.
PRIMARY OBJECTIVE: I. The primary objective for this pilot study is protocol adherence for the transfusion study we propose for pancreatectomy patients. SECONDARY OBJECTIVES: I. Determine the feasibility of collecting and processing of all data that will be collected in the full study. II. Specific emphasis will be given to findings from Patient Reported Outcomes Measurement Information System (PROMIS)-29 to determine its sensitivity to changes in health related quality of life (HRQOL) that occur in the perioperative period after pancreatectomy. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo red blood cell transfusion if hemoglobin (Hgb) is less than 7 g/dL while on study. ARM II: Patients undergo red blood cell transfusion if Hgb is less than 9 g/dL while on study. Patients undergo computed tomography (CT) scan, x ray imaging, and blood sample collection throughout the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT01333124 -
Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04858334 -
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
|
Phase 2 | |
| Completed |
NCT02562716 -
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT02427841 -
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT03823144 -
Intravital Microscopy in Human Solid Tumors
|
N/A | |
| Completed |
NCT02930902 -
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT03373188 -
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04560712 -
Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery
|
N/A |